KarenJVigilMDFACP, FIDSA(She/Her)
Infectious Disease • Houston, TXHIV/AIDS Medicine, STD Medicine
Professor, Internal Medicine, McGovern Medical School at The University of Texas Health Science Center, Houston. Associate Medical Director - HIV Services - Thomas Street at Quentin Mease - Harris Health. Quality Improvement Officer - Infectious Diseases - McGovern Medical School at UT Health, Houston
Dr. Vigil is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6431 Fannin St
MSB 2.112
Houston, TX 77030Phone+1 713-873-4000Fax+1 713-500-0730
Summary
- Dr. Karen Vigil is an infectious disease specialist in Houston, TX and is affiliated with multiple hospitals in the area, including Harris Health System and Memorial Hermann - Texas Medical Center. She received her medical degree from Cayetano Heredia University and has been in practice 16 years. She specializes in hiv/aids medicine and std medicine and is experienced in hiv/aids and infectious disease. She has more than 20 publications and over 300 citings.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Infectious Disease, 2006 - 2008
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 2003 - 2006
Cayetano Heredia UniversityClass of 2001
Certifications & Licensure
TX State Medical License 2009 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Respiratory Virus Outpatient Study (FLU 002 Plus) Start of enrollment: 2009 Aug 01
- Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP) Start of enrollment: 2011 May 01
- Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications Start of enrollment: 2010 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsSafety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phas...Chloe Orkin, Jean-Michel Molina, Pedro Cahn, Johannes Lombaard, Khuanchai Supparatpinyo
The Lancet. HIV. 2024-02-01 - Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?Angie Garcia, Karen J Vigil, Barbara Taylor, Onkar Kshirsagar, Mae Thamer
Journal of Viral Hepatitis. 2023-10-01 - 7 citationsImmunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus.Kristen M Marks, Minhee Kang, Triin Umbleja, Anchalee Avihingsanon, Patcharaphan Sugandhavesa
Clinical Infectious Diseases. 2023-08-14
Press Mentions
Pioneering Paper Shows Infection Control and Prevention in Clinics Is in Everyone’s HandsMay 3rd, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
